Clinical Trial Update: A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tremelimumab as monotherapy for malignant mesothelioma is being conducted; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Sponsor: Azienda Ospedaliera Universitaria Senese | Conditions: Malignant Mesothelioma | Phase 2 | Status: UNKNOWN